Generating destination analysis
Catalyst Play
Featured in “Three Biotech Stocks to Buy Before ASCO's Biggest Data Drop”
Beam Therapeutics pioneered base editing — next-generation gene editing that rewrites DNA without cutting it. Their precision approach dramatically reduces off-target effects. Phase 1/2 oncology data is imminent at ASCO. If it works, base editing becomes the new standard for genetic medicine.
The catalyst: The American Society of Clinical Oncology (ASCO) annual meeting — May 29 to June 2 in Chicago — is the most important event in cancer drug development. Over 40,000 oncology professionals gather for late-stage clinical trial data presentations that routinely move biotech stocks 30–50% in a single session. These three companies have the most anticipated data readouts at ASCO 2026, and the results will determine their trajectory for years.
Compass Direction
Earnings IntelligenceAI-Powered
Compass Score
Unlock Full BEAM Analysis
UpgradeKey Numbers
Market Cap
$3B
P/E
N/A
Revenue Growth
0.0%
Gross Margin
N/A
ROE
N/A
About Beam Therapeutics
Beam Therapeutics is a small-cap biotech company listed on the NASDAQ, positioned as a pure-play investment vehicle for the biotech and genomics megatrend. Base editing platform with differentiated gene-editing pipeline. With a $3B market capitalization and no current profitability, Beam Therapeutics has delivered revenue headwinds with revenue moving 0% over the past year.
Expert Coverage
Price & Technical Analysis
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
More in Biotech & Genomics
ARK Genomic Revolution ETF
ETF focused on companies advancing genomics, gene editing, and therapeutics.
DexCom Inc.
Continuous glucose monitoring leader expanding beyond diabetes management.
Alnylam Pharmaceuticals
RNA interference therapeutics leader with approved treatments for rare diseases.
Eli Lilly and Company
Pharma giant leading the GLP-1 revolution with Mounjaro and Zepbound weight-loss drugs.